%0 journal article
%@ 1079-5642
%A Hytoenen, J., Leppaenen, O., Braesen, J.H., Schunck, W.-H., Mueller, D., Jung, F., Mrowietz, C., Jastroch, M., Bergwelt-Baildon, M.V., Kappert, K., Heuser, A., Drenckhahn, J.-D., Pieske, B., Thierfelder, L., Ylae-Herttuala, S., Blaschke, F.

%D 2016
%J Arteriosclerosis, Thrombosis, and Vascular Biology : ATVB
%N 8
%P 1534-1548 
%R doi:10.1161/ATVBAHA.115.306962
%T Activation of Peroxisome Proliferator–Activated Receptor-Delta as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis
%U https://doi.org/10.1161/ATVBAHA.115.306962
8 
%X Conclusions—In contrast to commonly used drugs for stent coating, PPARδ ligands not only inhibit inflammatory response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. Thus, pharmacological PPARδ activation could be a promising novel strategy to improve drug-eluting coronary stents outcomes.